
-
Merus NasdaqGM:MRUS Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Location: Uppsalalaan 17, Utrecht, 3584 CT, Netherlands | Website: https://www.merus.nl | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
2.428B
Cash
458.3M
Avg Qtr Burn
-59.48M
Short % of Float
10.68%
Insider Ownership
1.85%
Institutional Own.
-
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
BIZENGRI® (zenocutuzumab-zbco) Details Cancer, Solid tumor/s, Non-small cell lung carcinoma, Pancreatic cancer | Approved Quarterly sales | |
Petosemtamab (MCLA-158) +/- Keytruda (pembrolizumab) Details Head and neck squamous cell carcinoma Suspected Mover™ Susp. Mover™ | Phase 2/3 Data readout | |
Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®) Details Solid tumor/s, Cancer, Metastatic colorectal cancer | Phase 2 Data readout | |
Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®) Details Metastatic colorectal cancer, Cancer | Phase 2 Data readout | |
Petosemtamab (MCLA-158) (Lgr5 x EGFR Biclonics®) in comb w/ SoC Details Solid tumor/s, Cancer, Metastatic colorectal cancer | Phase 2 Data readout | |
MCLA-129 (EGFR x c-MET Biclonics®) + Osimertinib Details Solid tumor/s, Cancer, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
MCLA-145 (CD137 x PD-L1 Biclonics®) + Keytruda Details Cancer, Solid tumor/s | Phase 1 Update |